Genomic assay can help identify breast cancer patients who may benefit from ovarian suppression therapy

A network of molecules and atoms of glass and crystals constitute a single system. 3D illustration

Among premenopausal women with hormone receptor (HR)-positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on a genomic assay called Breast Cancer Index (BCI) had increased risk of distant recurrence, and those with low BCI benefited more from the addition of ovarian suppression therapy to endocrine therapy after 12 years of follow-up, according to data presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

New method for early detection of multi-cancers based on human metabolism

Previous article

Exploring immunogenicity, boosting efficacy and safety of modified vaccinia Ankara-Bavarian Nordic vaccine

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News